GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » NeoGenomics Inc (STU:NG9) » Definitions » Cyclically Adjusted Price-to-FCF

NeoGenomics (STU:NG9) Cyclically Adjusted Price-to-FCF : (As of Jun. 10, 2024)


View and export this data going back to 2016. Start your Free Trial

What is NeoGenomics Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


NeoGenomics Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for NeoGenomics's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeoGenomics Cyclically Adjusted Price-to-FCF Chart

NeoGenomics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 484.39 1,172.56 - - -

NeoGenomics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of NeoGenomics's Cyclically Adjusted Price-to-FCF

For the Diagnostics & Research subindustry, NeoGenomics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeoGenomics's Cyclically Adjusted Price-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, NeoGenomics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where NeoGenomics's Cyclically Adjusted Price-to-FCF falls into.



NeoGenomics Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

NeoGenomics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, NeoGenomics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.23/131.7762*131.7762
=-0.230

Current CPI (Mar. 2024) = 131.7762.

NeoGenomics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.044 100.560 0.058
201409 0.034 100.428 0.045
201412 -0.001 99.070 -0.001
201503 -0.025 99.621 -0.033
201506 0.035 100.684 0.046
201509 0.028 100.392 0.037
201512 0.024 99.792 0.032
201603 0.072 100.470 0.094
201606 0.030 101.688 0.039
201609 0.088 101.861 0.114
201612 -0.030 101.863 -0.039
201703 -0.056 102.862 -0.072
201706 0.019 103.349 0.024
201709 0.054 104.136 0.068
201712 0.024 104.011 0.030
201803 0.097 105.290 0.121
201806 0.022 106.317 0.027
201809 0.059 106.507 0.073
201812 0.111 105.998 0.138
201903 0.027 107.251 0.033
201906 -0.071 108.070 -0.087
201909 0.095 108.329 0.116
201912 -0.023 108.420 -0.028
202003 -0.101 108.902 -0.122
202006 -0.026 108.767 -0.032
202009 -0.052 109.815 -0.062
202012 -0.036 109.897 -0.043
202103 -0.098 111.754 -0.116
202106 -0.144 114.631 -0.166
202109 -0.158 115.734 -0.180
202112 -0.229 117.630 -0.257
202203 -0.274 121.301 -0.298
202206 -0.208 125.017 -0.219
202209 -0.196 125.227 -0.206
202212 -0.062 125.222 -0.065
202303 -0.169 127.348 -0.175
202306 -0.067 128.729 -0.069
202309 -0.073 129.860 -0.074
202312 0.078 129.419 0.079
202403 -0.230 131.776 -0.230

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


NeoGenomics  (STU:NG9) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


NeoGenomics Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of NeoGenomics's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


NeoGenomics (STU:NG9) Business Description

Traded in Other Exchanges
Address
9490 NeoGenomics Way, Fort Myers, FL, USA, 33912
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Pharma Services. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. The company generates revenue from Clinical Services.

NeoGenomics (STU:NG9) Headlines

No Headlines